摘要
研究帕博利珠单抗对晚期肺腺癌患者血清肿瘤标志物癌胚抗原(CEA)、糖类癌抗原50(CA50)、糖类癌抗原242(CA242)的影响。选择2018年1月至2021年1月在本院收治的120例晚期肺腺癌患者作为研究对象,观察组(60例)采用帕博利珠单抗+培美曲塞+卡铂化疗,对照组(60例)采用安慰剂+培美曲塞+卡铂化疗,治疗4个周期后评估两组患者的临床疗效,检测血清肿瘤标志物及免疫因子水平,记录治疗期间的不良反应。治疗前,观察组患者的性别、年龄、ECOG评分、吸烟史等基线资料及血清CEA、CA50、CA242水平与对照组相比,无统计学差异(P>0.05)。治疗后,观察组的总有效率(51.67%)显著高于对照组(31.67%)(P<0.05);观察组的血清CEA、CA50、CA242水平均显著低于对照组(P<0.05);治疗后2组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平均高于治疗前,观察组均高于对照组(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。帕博利珠单抗可有效降低晚期肺腺癌患者的血清CEA、CA50、CA242水平,提高治疗效果,安全性良好,值得临床推广使用。
To investigate the effect of parolizumab on serum tumor markers carcinoembryonic antigen(CEA),carbohydrate cancer antigen 50(CA50),and carbohydrate cancer antigen 242(CA242)in patients with advanced lung adenocarcinoma,a total of 120 patients with advanced lung adenocarcinoma admitted to the hospital from January 2018 to January 2021 were selected as the study subjects.The observation group(60 cases)received chemotherapy with parolizumab+pemetrexed+carboplatin,while the control group(60 cases)received chemotherapy with placebo+pemetrexed+carboplatin.After 4 cycles of treatment,the clinical efficacy of the two groups of patients was evaluated,serum tumor markers and immune factor levels were measured,and adverse reactions during treatment were recorded.Before treatment,there was no significant difference in baseline data such as gender,age,ECOG score,smoking history,and serum CEA,CA50,and CA242 levels between the observation group and the control group(P>0.05).After treatment,the total effective rate in the observation group(51.67%)was significantly higher than that in the control group(31.67%,P<0.05);The serum CEA,CA50,and CA242 levels in the observation group were significantly lower than those in the control group(P<0.05);After treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in both groups were higher than those before treatment,while those in the observation group were higher than those in the control group(P<0.05).There was no signifi⁃cant difference in the incidence of adverse reactions between the two groups(P>0.05).Pabolizumab can effectively reduce the serum levels of CEA,CA50,and CA242 in patients with advanced lung adenocarcinoma,improve the therapeutic effect,and have good safety.It is worth promoting and using in clinical practice.
作者
曲叶倩
陈勇
江启安
汪志求
李承慧
QU Ye-qian;CHEN Yong;JIANG Qi-an;WANG Zhi-qiu;LI Cheng-hui(Department of Medical Oncology,Anqing Municipal Hospital,Anqing 246003,China;General Surgery De-partment,Jiuting Hospital,Songjiang District,Shanghai 201615,China)
出处
《药物生物技术》
CAS
2023年第4期374-378,共5页
Pharmaceutical Biotechnology
基金
上海市松江区科学技术攻关项目(No.19SJKJGG140)。
关键词
肺腺癌
晚期
帕博利珠单抗
化疗
肿瘤标志物
糖类癌抗原
安全性
Lung adenocarcinoma
Advanced
Pabolizumab
Chemotherapy
Tumor markers
Carbohydrate cancer antigen
Security
作者简介
曲叶倩(1983⁃),女,汉族,安徽安庆人,本科,主治医师,研究方向:肺腺癌,E⁃mail:dsgday@126.com;通信作者:李承慧(1977⁃),女,汉族,安徽安庆人,硕士研究生,主任医师,研究方向:恶性肿瘤免疫治疗及内科综合治疗,E⁃mail:lchui001@163.com。
